» Articles » PMID: 38887294

Regulatory and Memory T Lymphocytes Infiltrating Prostate Tumors Predict Long Term Clinical Outcomes

Overview
Journal Front Immunol
Date 2024 Jun 18
PMID 38887294
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The localization, density but mostly the phenotype of tumor infiltrating lymphocytes (TIL) provide important information on the initial interaction between the host immune system and the tumor. Our objective was to assess the prognostic significance of T (CD3), T regulatory (T) (FoxP3) and T memory (T) (CD45RO) infiltrating lymphocytes and of genes associated with TIL in prostate cancer (PCa).

Methods: Immunohistochemistry (IHC) was used to assess the infiltration of CD3, FoxP3 and CD45RO cells in the tumor area, tumor margin and adjacent normal-like epithelium of a series of 98 PCa samples with long clinical follow-up. Expression of a panel of 31 TIL-associated genes was analyzed by Taqman Low-Density Array (TLDA) technology in another series of 50 tumors with long clinical follow-up. Kaplan-Meier and Cox proportional hazards regression analyses were performed to determine association of these markers with biochemical recurrence (BCR), need for definitive androgen deprivation therapy (ADT) or lethal PCa.

Results: TIL subtypes were present at different densities in the tumor, tumor margin and adjacent normal-like epithelium, but their density and phenotype in the tumor area were the most predictive of clinical outcomes. In multivariate analyses, a high density of T (high FoxP3/CD3 cell ratio) predicted a higher risk for need of definitive ADT (HR=7.69, p=0.001) and lethal PCa (HR=4.37, p=0.04). Conversely, a high density of T (high CD45RO/CD3 cell ratio) predicted a reduced risk of lethal PCa (HR=0.06, p=0.04). TLDA analyses showed that a high expression of FoxP3 was associated with a higher risk of lethal PCa (HR=5.26, p=0.02). Expression of CTLA-4, PD-1, TIM-3 and LAG-3 were correlated with that of FoxP3. Amongst these, only a high expression of TIM-3 was associated with a significant higher risk for definitive ADT in univariate Cox regression analysis (HR=3.11, p=0.01).

Conclusion: These results show that the proportion of T and T found within the tumor area is a strong and independent predictor of late systemic progression of PCa. Our results also suggest that inhibition of TIM-3 might be a potential approach to counter the immunosuppressive functions of T in order to improve the anti-tumor immune response against PCa.

Citing Articles

Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.

Park M, Choi J, Maharub Hossain Fahim M, Asevedo E, Nurkolis F, Ribeiro R Front Pharmacol. 2025; 16:1504618.

PMID: 40034825 PMC: 11872924. DOI: 10.3389/fphar.2025.1504618.


CD4 T cells in antitumor immunity.

Montauti E, Oh D, Fong L Trends Cancer. 2024; 10(10):969-985.

PMID: 39242276 PMC: 11464182. DOI: 10.1016/j.trecan.2024.07.009.

References
1.
Sakaguchi S, Miyara M, Costantino C, Hafler D . FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010; 10(7):490-500. DOI: 10.1038/nri2785. View

2.
Kaur H, Guedes L, Lu J, Maldonado L, Reitz L, Barber J . Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod Pathol. 2018; 31(10):1539-1552. PMC: 6168349. DOI: 10.1038/s41379-018-0083-x. View

3.
Wang L, Lu B, He M, Wang Y, Wang Z, Du L . Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front Public Health. 2022; 10:811044. PMC: 8888523. DOI: 10.3389/fpubh.2022.811044. View

4.
Guedes L, Antonarakis E, Schweizer M, Mirkheshti N, AlMutairi F, Park J . MSH2 Loss in Primary Prostate Cancer. Clin Cancer Res. 2017; 23(22):6863-6874. PMC: 5690834. DOI: 10.1158/1078-0432.CCR-17-0955. View

5.
Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View